Haemonetics (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company’s hospital portfolio is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism. Meanwhile, headwinds from economic uncertainties and adverse foreign exchange effects are concerns for Haemonetics’ operations. In the past year, this Zacks Rank #2 (Buy) stock has rallied 11.7% against the 1.3% fall of the indus ...